Frontlight ResearchEarly access
WithdrawnNo phase
Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
Key facts
- Who runs it
- Case Comprehensive Cancer Center
- Where
- Cleveland, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 30 Dec 2023
- Ended
- 30 Jun 2024
- Type of study
- Observational
- Treatments tested
- SignateraTM assay
- Record updated
- 12 April 2024
- Why it stopped
- Sponsor already published research that was to be obtained from this study.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Newly histologically documented rectal adenocarcinoma or biopsy-proven adenoma with MRI rectum and CT chest/abdomen or PET/CT imaging consistent with stage II or III disease
- Plan is for participant to undergo standard TNT with induction chemoradiation
- Age ≥ 18 years of age
Who cannot take part
- Received prior therapy for this rectal cancer
- Stage I, recurrent, or metastatic rectal cancer
- No baseline tumor biopsies with adenocarcinoma or adequate amount of tissue from biopsies available to send for SignateraTM assay development
Where in United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer CenterCleveland, United States
About the trial
What the trial wants to find out
The purpose of this study is to use the SignateraTm assay created from rectal tumor biopsies to monitor participants' blood for fragments of DNA shed by tumor cells. The tumor DNA fragments are referred to as circulating tumor DNA, or ctDNA for short.
Treatments tested
- SignateraTM assay
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 April 2024